Bone Biologics Corporation (BBLGW) Operating income 2016–2025
Bone Biologics Corporation (BBLGW) annual operating income history from SEC filings — each fiscal year as reported.
-$3.2MFY2025 · since FY2016: -$20.4M → -$3.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$3.2M | +23.3% |
| FY2024 | -$4.2M | +55.3% |
| FY2023 | -$9.4M | -157.2% |
| FY2022 | -$3.7M | -232.3% |
| FY2021 | -$1.1M | -33.7% |
| FY2020 | -$825,014 | +66.3% |
| FY2019 | -$2.4M | +12.3% |
| FY2018 | -$2.8M | -6.3% |
| FY2017 | -$2.6M | +87.1% |
| FY2016 | -$20.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More BBLGW financial trends
BBLGW RevenueBBLGW Net incomeBBLGW Net marginBBLGW Gross profitBBLGW Gross marginBBLGW Operating marginBBLGW Operating cash flowBBLGW Free cash flowBBLGW Capital expendituresBBLGW Return on equityBBLGW Stock buybacksBBLGW Dividends paidBBLGW Total assetsBBLGW Total liabilitiesBBLGW Shareholders’ equityBBLGW overview →